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Abstract
Purpose: The cytomegalovirus (CMV) promoter is one of the most commonly used promoters for
expression of transgenes in mammalian cells. The aim of our study was to evaluate the role of
methylation and upregulation of the CMV promoter by irradiation and the chemotherapeutic
agent cisplatin in vivo using non-invasive fluorescence in vivo imaging.
Procedures: Murine fibrosarcoma LPB and mammary carcinoma TS/A cells were stably
transfected with plasmids encoding CMV and p21 promoter-driven green fluorescent protein
(GFP) gene. Solid TS/A tumors were induced by subcutaneous injection of fluorescent tumor
cells, while leg muscles were transiently transfected with plasmid encoding GFP under the
control of the CMV promoter. Cells, tumors, and legs were treated either by DNA methylation
inhibitor 5-azacytidine, irradiation, or cisplatin. GFP expression was determined using a
fluorescence microplate reader in vitro and by non-invasive fluorescence imaging in vivo.
Results: Treatment of cells, tumors, and legs with 5-azacytidine (re)activated the CMV promoter.
Furthermore, treatment with irradiation or cisplatin resulted in significant upregulation of GFP
expression both in vitro and in vivo.
Conclusions: Observed alterations in the activity of the CMV promoter limit the usefulness of this
widely used promoter as a constitutive promoter. On the other hand, inducibility of CMV
promoters can be beneficially used in gene therapy when combined with standard cancer
treatment, such as radiotherapy and chemotherapy.
Key words: CMV promoter, Fluorescence imaging, Irradiation, Cisplatin, Demethylation, In vivo,
Mice, Mammary carcinoma, Fibrosarcoma
Introduction
Immediate/early promoter/enhancer of cytomegalovirus(CMV promoter) is one of the most commonly used
promoters for expression of transgenes in mammalian cells
for research or therapeutic purposes. Although it is often
thought of as a constitutive and unregulated pan-specific
promoter, it has been shown that its activity is strongly
dependent on the host-cell transcriptional environment.
Many reports demonstrated that it does not direct persistent
transgene expression and that its transcriptional activity
varies according to cell type and developmental age and can
also be upregulated under specific conditions [1–13].
DNA methylation of the promoter is the most frequently
given explanation for transient gene expression of theCorrespondence to: Maja Cemazar; e-mail: mcemazar@onko-i.si
transgene constructs containing the CMV promoter, inde-
pendently of the delivery system used [1–5]. For instance,
the CMV promoter was shown to be susceptible to tran-
scriptional inactivation by methylation after transient trans-
fection using different non-viral delivery vectors [2, 4, 5].
The same observation was also demonstrated for a stably
transfected cell line using lipofection in vitro [3]. Inhibition
of transgene expression caused by methylation of the CMV
promoter was also reported in vivo following adenoviral
gene delivery to muscle [1]. On the other hand, some studies
demonstrated that methylation is not always responsible for
the observed transient expression in vivo. For instance,
methylation was investigated as a potential cause of the
transient transgene expression from non-viral vectors in the
mouse lung, but results suggested that the plasmid DNA
does not become de novo methylated in the mouse airways
[6]. Similarly, transcriptional inactivation of CMV after
adenovirus gene transfer was demonstrated in the mouse
liver although there was no evidence for the methylation of
adenovirus DNA [7]. In the later study [7], silenced CMV
promoter was reactivated after treatment with lipopolysac-
charide (LPS). There have also been other reports suggesting
that the CMV promoter can be upregulated under specific
conditions such as treatment with LPS, cyclic AMP, phorbol
esters, bacterial CpGs [8–11], and by a variety of environ-
mental stresses [12]. Recently, chemotherapeutic agents and
radiation (IR) were shown to upregulate expression of
transgenes driven by the CMV promoter in vitro and in
vivo [13, 14]. Upregulation with chemotherapeutics was
reported to occur in multiple cell lines independently of the
transfection method used [14], and radiation was reported to
enhance adenoviral gene therapy in pancreatic cancer via
activation of the CMV promoter [13].
Non-invasive whole body optical methods (luminescence
or fluorescence) are very competitive approaches to assess
tumor development and responses to drug and gene therapies
in vivo and are far more affordable compared to other
imaging methods, such as positron emission tomography, X-
ray computed tomography, and magnetic resonance imaging
[15, 16]. Recently, they were employed also for following
transgene expression and activity of promoters in vivo.
However, the in vivo reports on methylation and upregula-
tion of the CMV promoter by conventional treatments, such
as IR and cisplatin (CDDP), are scarce; and results are
contradictory [1, 6, 7, 14, 17]. Therefore, the aim of our
study was to evaluate the role of methylation and upregu-
lation of the CMV promoter by IR and CDDP in vivo using
non-invasive fluorescence in vivo imaging, which enables
long-term follow-up of reporter gene fluorescence in the
animals and consequently, the activity of promoters that
control reporter gene expression. Different systems in which
expression of the reporter gene was controlled either by an
inducible promoter or CMV promoter (stable cell lines,
stably transfected experimental tumors, and transiently
transfected muscles) were set up using the non-viral delivery
system of electroporation and the influence of treatment with
5-azacytidine, IR, and CDDP on the activity of the CMV
promoter in vitro and in vivo was assessed.
Materials and Methods
Plasmids
A plasmid encoding green fluorescence protein (GFP) under the
control of the CMV promoter and neomycin resistance gene
(pEGFP-N1, Clontech, Basingstoke, UK) and a plasmid encoding
GFP under the control of the human p21 promoter and neomycin
resistance gene (p21-EGFP, kind gift from Irena Hreljac, National
Institute of Biology, Ljubljana, Slovenia) were used. Human p21
promoter is an inducible mammalian promoter that is induced by
DNA damage [18, 19]. In the study, it was used as a control for
the CMV promoter.
Cell Lines
Murine adenocarcinoma of the mammary glands TS/A [20] and
murine fibrosarcoma LPB [21] cell lines were maintained in
Eagle’s minimum essential medium (EMEM, Sigma, Taufkirchen,
Germany), supplemented with 10% fetal calf serum (Sigma,
Taufkirchen, Germany), 2 mM L-glutamine, 1 mM sodium
pyruvate, and 100 IU/ml penicillin/streptomycin (Pliva, Zagreb,
Croatia) in a 5% CO2 humidified incubator at 37°C.
Preparation of Stable Cell Lines Carrying CMV
or p21 Promoter-Driven Reporter Gene Constructs
LPB and TS/A cells were transfected with the pEGFP-N1 plasmid
and the LPB cell line was transfected with the p21-EGFP plasmid.
Electroporation was used for introduction of plasmid DNA into
cells. Specifically, cells grown as a monolayer were harvested and a
2.5×107 cells/ml cell suspension was prepared in electroporation
buffer (125 mM sucrose, 10 mM K2HPO4, 2.5 mM KH2PO4, 2 mM
MgCl2×6 H2O). A dense cell suspension with a concentration of
1×106 cells and 10 μg of pEGFP-N1 in 50 μl of electroporation
buffer was placed between two flat parallel stainless steel
electrodes with a 2 mm gap connected to the GT-1 electroporator
(University of Ljubljana, Faculty of Electrical Engineering,
Ljubljana, Slovenia) and subjected to eight square-wave electric
pulses with an amplitude per distance ratio 700 V/cm, 5 ms
duration time, and 1 Hz repetition frequency. After electroporation
cells were incubated for 5 min at room temperature, plated into
Petri dishes, and then cultured for 2 months under increasing
concentrations (500–1,000 μg/ml for LPB cells and 1,200–
2,000 μg/ml for TS/A cells) of the selection agent geneticin
(Gibco Invitrogen, San Diego, CA, USA) to obtain resistant
clones. Clones with the highest GFP expression were identified by
fluorescence microscopy (Olympus, Hamburg, Germany), isolated,
propagated, and frozen in liquid nitrogen for subsequent experi-
ments. To determine the number of fluorescent cells, flow
cytometry analysis of stable cell lines carrying CMV promoter-
driven reporter gene constructs was performed: cells were trypsi-
nized, collected, and 2×104 cells from each stable line were
analyzed using flow cytometry (Becton Dickinson, Calibur,
Franklin Lakes, NJ, USA). The percentage of cells stably
expressing GFP was determined from the histograms.
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Study Design In Vitro
To test the influence of DNA methylation and treatment with IR or
CDDP on CMV activity in in vitro conditions, cells were treated with
the DNA methylation inhibitor 5-azacytidine (5-aza-2dC, Sigma) and
exposed to IR and CDDP (cis-diamminedichloroplatinum (II),
Pharmacia & Upjohn S.p.A, Milan, Italy). For the methylation tests,
cells were first passaged for 1 month to allow methylation of DNA to
occur and then (at the sixth passage) treated with a DNA methylation
inhibitor, while for the IR and CDDP exposure freshly thawed (first
passage) cells were used. The treatment protocols were as follows:
 5-aza-2dC: Cells were plated at a density of 1.5×104 cells/cm2 and
treated with 5-aza-2dC for 3 days. A stock solution of 5-aza-2dC was
prepared in phosphate buffered saline (PBS) and was freshly diluted to a
working concentration of 1 μM in EMEM each day of the experiment.
 IR: Cells were plated at a density of 1.7×104 cells/cm2 and irradiated
with a dose of 6 Gy using an X-ray unit Drapac 2000 (Gulmay Medical
Ltd, Shepperton, UK) operating at 220 kV, 10 mA, and with 0.55 mm
Cu and 1.8 mm Al filtration.
 CDDP: CDDP in the form of crystalline powder was dissolved in sterile
H2O at a stock concentration of 2 mg/ml. Cells were plated at a density
of 2.0×104 cells/cm2 and the stock solution of CDDP was added to
EMEM to get a working concentration of 3 μg/ml.
Three days after the treatments, cells were trypsinized, collected,
and 2×105 cells were plated in 96-well microplates. Expression of
the reporter gene was determined using the fluorescence microplate
reader Infinite 200 (Tecan, Männedorf, Switzerland) and fluores-
cence microscopy (Olympus, Hamburg, Germany)
Experimental Animals
For the in vivo experiments, female BALB/c and female C57BL/6
mice obtained from the Institute of Pathology, Faculty of Medicine,
University of Ljubljana, Slovenia were used. At the beginning of
the experiments, the animals were 10–12 weeks old. Mice were
housed and maintained in a specific pathogen-free animal colony at
constant room temperature (21ºC) and 12 h light/dark cycle. Food
and water were provided ad libitum. Animals were subjected to an
adaptation period of 7–10 days before the experiments were carried
out. All procedures on animals were performed in accordance with the
official guidelines of the Ministry of Agriculture, Forestry, and Food
of the Republic of Slovenia (permission no. 323-02-632/2005/6).
Induction of Solid Subcutaneous Tumors
Viable TS/A EGFP tumor cells (2×106) prepared from cell culture
in vitro were injected dorsolaterally in BALB/c mice. When the
tumors reached approximately 40 mm3 in volume (7–10 days),
mice were randomly divided into experimental groups and
subjected to a specific experimental protocol.
Preparation of Transiently Transfected Muscle
Model Carrying CMV Promoter-Driven Reporter
Gene Construct
C57Bl/6 mice were anesthetized with isofluran (Torrex Chiesi
GmbH, Wien, Austria) using an isoflurane vaporizer (Datex
Ohmeda, Helsinki, Finland). Plasmid pEGFP-N1 (20 μg in 20 μl
of water) was injected into both m. tibialis cranialis with a thin
(26 G) needle. The hind legs were placed between two flat parallel
stainless steel electrodes with rounded corners (dimensions
20 mm×10 mm) with a 6 mm gap between the electrodes con-
nected to the electric pulse generator Cliniporator™ (IGEA s.r.l.,
Carpi, Italy) and subjected to one high-voltage square-wave electric
pulse with an amplitude per distance 600 V/cm and 100 μs duration
and four low-voltage square-wave electric pulses with an amplitude
per distance 80 V/cm, 100 ms duration, and 1 Hz repetition
frequency [22]. Good contact between the electrodes and legs was
assured by hair removal using hair removal cream (Vitaskin, Krka,
d.d., Novo mesto, Slovenia) and use of a conductive gel (Kameleon
d.o.o., Maribor, Slovenia). When the fluorescence intensity
declined to ∼50% of the highest level [23] (approximately 4 weeks
after transfection), mice were randomly divided into experimental
groups and subjected to a specific experimental protocol.
Study Design In Vivo
To test the influence of DNA methylation and treatment with IR
and CDDP on CMV activity in vivo, tumor-bearing BALB/c mice
and C57BL/6 mice with transiently transfected muscles were
treated with either 5-azacytidine, IR, or CDDP. The treatment
protocols were as follows:
 5-aza-2dC: Mice were treated twice by intraperitoneal
injection of 0.2 mg/kg of 5-azacytidine in 300 μl of PBS
on two consecutive days. A stock solution of 5-aza-2dC
was freshly diluted to the working concentration each day
of the experiment.
 IR: Tumors and transfected muscles were irradiated with
a dose of 6 Gy using the same X-ray unit as used for the
in vitro experiments. During irradiation, mice were
restrained in special lead holders with apertures for
irradiation of the tumors/legs, exposing only the tumors/
legs and shielding the rest of the body from irradiation.
 CDDP: Mice were injected intravenously with 8 mg/kg of
cisplatin in 100 μl of sterile H2O. For each experiment, a
fresh stock solution was prepared from crystalline powder
and diluted to the working concentration.
In Vivo Non-Invasive Fluorescence Imaging
After the treatments, fluorescence intensity of the tumors and
muscles expressing GFP was followed transcutaneously using a
fluorescence stereo microscope, which enabled non-invasive
follow-up of the intensity and duration of GFP expression. For
each observation under the microscope, hair over the tumor or
muscle was removed using an electric shaver and/or hair removal
cream and animals were anesthetized with isoflurane as described
above.
Digital images of fluorescence were recorded everyday post-
treatment for 8 days for tumors and every 2–3 days for 12 days in
the case of the muscle with a digital color camera (Axiocam MRc5,
Zeiss, Jena, Germany) connected to the fluorescence stereo micro-
scope (Lumar.V12, Zeiss, Jena, Germany). During capture, tumors
or legs were placed in a special holder to minimize the movement
of animals caused by breathing and to ensure the same positioning
at each observation.
Images were analyzed using the ImageJ software tool (National
Institute of Mental Health, Research Services Branch, Bethesda,
MA, USA). Images of the same tumor (Fig. 1) or muscle (Fig. 2)
taken at different time points were stacked together, and the
fluorescence intensity was determined by adjusting the threshold
values for each stack. Adjusted mean fluorescence intensity of each
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tumor or muscle picture in the stack was then normalized to the
mean fluorescence intensity at day 0.
Statistical Analysis
The data were tested for normality of distribution using the
Kolmogorov–Smirnov test. Differences between experimental
groups were statistically evaluated by the Student’s t test. A P
value of less than 0.05 was considered to be statistically significant.
Statistical analysis was performed using SigmaStat software (Systat
Software Inc., San Jose, CA, USA).
Results
Stably Transfected Cell Lines
LPB and TS/A stable lines expressing the GFP reporter gene
under the control of the CMV promoter were prepared and
designated as LPB EGFP and TS/A EGFP, and the LPB cell
line expressing GFP under the control of the p21 promoter
was prepared and designated as LPB p21-EGFP. Flow
cytometry analysis showed that 70% of cells stably
expressed GFP in the TS/A EGFP cell line and only 20%
in the LPB EGFP cell line, whereas in the LPB p21-EGFP
cell line almost all cells expressed GFP (93%; Fig. 3).
Influence of DNA Methylation on CMV
Inactivation In Vitro
Cells were first passaged for 1 month (six passages) to allow
methylation of DNA to occur. During this time, fluorescence
intensity decreased by a factor of 2.8 in TS/A EGFP and by
1.2 in LPB EGFP, but not in LPB p21-EGFP cells. After
treatment with 5-aza-2dC, a statistically significant increase
in fluorescence intensity was obtained in TS/A EGFP and
LPB EGFP cell lines by a factor of 6.9 and 1.4 compared to
the control (sixth passage), respectively. The increase in the
LPB p21-EGFP cell line was by a factor of 1.3 (Fig. 4).
IR- and CDDP-Induced Regulation of the CMV
Promoter
Exposure of cells to IR or CDDP resulted in significant
upregulation of expression in both cell lines with the CMV
promoter, although the effects were more evident in the TS/
A EGFP cell line. After IR, fluorescence intensity increased
1.82-fold in TS/A EGFP and 1.05-fold in LPB EGFP cells
compared to the control. After treatment with CDDP, the
increase in fluorescence intensity was comparable to that
after IR and was 1.73-fold in the TS/A EGFP cell line and
1.03-fold in the LPB EGFP cell line. In the control group
with the inducible p21 promoter the induction was by a
factor of 1.29 after IR and 1.81 after CDDP compared to the
control (Fig. 5).
Influence of DNA Methylation and Treatment
with IR and CDDP on CMV Activity In Vivo
Treatment of tumors 7–10 days post-induction with 5-aza-
2dC did not significantly increase fluorescence intensity of
TS/A EGFP tumors during the observation period. Only a
trend of increased fluorescence intensity towards the end of
the observation period was observed. However, in the
transiently transfected muscles, treatment with 5-aza-2dC
4 weeks post-transfection resulted in significantly increased
fluorescence intensity towards the end of the observation
period on day 12 by a factor of 1.40 (Fig. 6).
Treatment with IR or CDDP resulted in significant
upregulation of GFP expression in both in vivo models (pG
0.05, vs. control). After IR, the fluorescence intensity of TS/
A EGFP tumors was significantly increased by a factor of
1.26 already on the third day after treatment and by a factor
of 1.24 on the fourth day. Similarly, the increase in
fluorescence intensity of transiently transfected muscles
following IR was by a factor of 1.17 on the second day
and by a factor of 1.25 on the fifth day post-treatment.
Systemic treatment with CDDP upregulated the CMV
promoter, resulting in significantly increased fluorescence
intensity in both TS/A EGFP tumors and transiently trans-
fected muscles. Upregulation was the most pronounced on
Fig. 1. a Fluorescent image of the tumor. b Fluorescence of tumors was separated from background fluorescence using the
lower threshold value (blue). The upper threshold value (green) was used to exclude necrotic areas of the tumor.
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the fourth day post-treatment for tumors and on the fifth day
for muscles with a factor of increase 1.35 and 1.18,
respectively (Fig. 6).
Discussion
The results of our study demonstrate that the CMV promoter
cannot be considered a constitutive promoter. We show that
it is silenced with time and that it can be (re)activated after
treatment with a demethylating agent. We also showed that
the CMV promoter can be induced by treatment with IR and
CDDP in stably transformed cell lines in vitro and in vivo
and after transient delivery to muscle. Furthermore, we
demonstrated that non-invasive fluorescence imaging is an
appropriate and convenient method to monitor the activity of
the promoter in vivo.
Sustained and well-defined or controllable expression
levels of the transgene are desired characteristics of
mammalian gene expression vectors used for research or
therapeutic purposes. Since expression levels of transgenes
are dependent on the promoter, proper choice of promoter
linked to the gene of interest is essential for the success of
these vectors, especially if they are going to be used in
human gene therapy. The CMV promoter is one of the most
commonly used promoters for expression of transgenes in
mammalian cells. Despite the fact that many reports
demonstrated that its transcriptional activity can be changed
under specific conditions, it is still used as a constitutive
promoter in many in vitro and in vivo studies and even in
clinical gene therapy trials [24].
The basis of our experiments was construction of differ-
ent systems (stably transfected cell lines, stably transfected
tumors, and transiently transfected muscles) in which
expression of the GFP reporter gene was regulated either
by the inducible p21 or CMV promoter. These systems
allowed us to follow promoter activity simply by quantifying
fluorescence intensities either by fluorescence microscopy
and fluorometer in vitro or by non-invasive in vivo imaging
using a fluorescence stereomicroscope, assuming that fluo-
rescence of the cells is proportional to promoter-driven
expression.
For construction of stably transfected tumor cell lines,
two histologically different murine cell lines were used:
mammary adenocarcinoma and fibrosarcoma. At the end of
the culturing period in the selection agent, the percentage of
cells expressing GFP differed between the cell lines. The
observed difference can be ascribed to the cellular specificity
of the CMV promoter. Namely, studies demonstrated that
the CMV promoter exhibits cellular specificity and that it is
active only in cell types which are naturally infected by the
virus [11, 25, 26]. These studies were done on transgenic
mice expressing a reporter gene under the control of CMV,
Fig. 2. a Fluorescent image of the muscle. b Fluorescence of muscle fibers was separated from the non-transfected region of
the leg and background fluorescence by adjusting the lower threshold value (blue).
Fig. 3. Histograms of GFP fluorescence in a LPB EGFP, b LPB p21-EGFP, and c TS/A EGFP cells.
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thus, in non-transformed non-cancer cells. In our case, TS/A,
which is murine adenocarcinoma of the mammary glands,
and LPB, which is murine fibrosarcoma, cell lines were
used. Although the cell lines in our study were transformed
cancer cell lines, they are derived from two different cell
types. Therefore, it can be speculated that differences in the
percentage of stably transfected cells were due to the
inherent differences in these cell lines with regard to
susceptibility to infection with CMV.
Another observation during the preparation of stable cell
lines was that initial high fluorescence intensity decreased
after every round of replication in cell lines with the CMV
promoter, but not in the cell line with the p21 promoter.
Several mechanisms for the transient expression of the
delivered transgene have been described in the literature,
such as loss of vector DNA from the transduced cells and
transcriptional inactivation of the promoter [27, 28]. In our
case, the loss of vector DNA could not be a major limiting
factor for sustained transgene expression, since “stably”
transfected cells were resistant to increasing concentrations
of geneticin, meaning that they expressed the selective
marker encoded on the plasmid, which demonstrates that the
plasmid DNA is present in the cells. In addition, results of
our previous study, showing that long-term transgene
expression can be maintained even after transient trans-
fection in muscle, support the argument that the major cause
for the observed loss of transgene expression was promoter
inactivation rather than the loss of plasmid [23].
DNA methylation of the promoter is the most frequent
justification for inactivation of the promoter [1, 2, 4, 5, 29].
The process of promoter methylation is mediated by a class
of enzymes that covalently link a methyl group to the
promoter region of the gene leading to modification of
accessibility of transcriptional factors to the promoter. To
test if the observed decrease in reporter gene expression in
our study was due to methylation of the CMV promoter,
freshly thawed cells were first passaged for 1 month to allow
methylation of DNA to take place and then treated with the
demethylation agent 5-aza-2dC, which is one of the best
characterized drugs used for reactivation of methylated
Fig. 4. Visible and fluorescence images of a TS/A EGFP, b LPB EGFP, and c LPB p21-EGFP cells. d Influence of treatment
with 5-aza-2dC on CMV promoter reactivation. All data were pooled from three independent experiments performed in 12
replicates. Results are expressed as the mean ± SE (*PG0.05).
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promoters [2, 30–32]. The fluorescence intensity of the first
passage of freshly thawed cells was taken as the reference
for the unmethylated state. After the treatment, an obvious
increase in fluorescence was obtained, which was more
pronounced in the TS/A EGFP cell line (6.9×) than in the
LPB EGFP cell line (1.4×). Similar to our results, reactiva-
tion of CMV-driven reporter gene expression after treatment
with 5-aza-2dC was reported in a study using lipofection to
stably transfect a human glioblastoma cell line [3].
Interestingly, in our study, the increase in fluorescence
after (re)activation was higher than would be expected from
the reference (fluorescence intensity of the cells from the
first passage), especially in the TS/A cell line, indicating that
some other mechanisms were involved in the observed (re)
activation. One of them could be upregulation induced by
cytotoxic stress. Namely, in addition to its demethylating
function, 5-aza-2-dC has also been shown to possess
significant cytotoxic and anticancer activity. In fact, it was
originally developed as an anticancer agent and was as such
used in many preclinical and clinical trials [33]. There are
two lines of evidence supporting the involvement of stress in
the observed upregulation in our study. The first is that some
upregulation occurred also after treatment with 5-aza-2dC in
the control group with the p21 promoter. These results are in
accordance with other studies [34–38], where cytotoxicity of
5-aza-2dC was linked to its ability to induce DNA damage,
leading to activation of the p53 and consequently p21
pathways. The next line of evidence supporting the involve-
ment of stress is upregulation of the CMV promoter which
was obtained after exposure of cells to IR and treatment with
CDDP. Therefore, the increase in fluorescence intensity
above the reference value in the two stably transfected cell
lines with the CMV promoter is most probably the sum of
demethylation of the CMV promoter and upregulation of the
CMV promoter due to the cytotoxic action of 5-aza-2dC.
However, to fully validate the involvement of DNA
methylation in the (re)activation of the CMV promoter,
further experiments, such as methylation-sensitive restriction
enzyme analysis, should be performed [7].
To test whether inactivation of the CMV promoter also
occurs in in vivo conditions, in vitro results were verified by
in vivo imaging in a tumor-bearing mouse model. We only
used the TS/A EGFP tumor model since the reporter gene
expression in the LPB EGFP cell line was too low and could
Fig. 5. Visible and fluorescence images of a TS/A EGFP, b LPB EGFP, and c LPB p21-EGFP cells. d IR and CDDP induced
upregulation of the CMV promoter. All data were pooled from three independent experiments performed in 12 replicates.
Results are expressed as the mean ± SE (*PG0.05).
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not be detected transcutaneously due to technical limitations
of the fluorescence stereomicroscope. In the TS/A EGFP
tumors, the effects of treatment with 5-aza-2dC were not as
obvious as in vitro; only the trend of increased fluorescence
intensity was indicated. The reason for the observed differ-
ence between the in vitro and in vivo results is most probably
due to the fast growth of tumors which limit the duration of
the experiment (10 days compared to 1 month used in in
vitro experiments) and consequently the time needed for
methylation to occur. This observation is also supported by
the fact that the trend was more pronounced toward the end
of the experiment. To our knowledge, our study is the first
study dealing with methylation of the CMV promoter in
tumors. Other studies dealing with methylation of CMV
were done in normal tissues and their results are incon-
sistent. Association of transcriptional silencing with methyl-
ation of the CMV promoter was demonstrated in rat muscles
using adenoviral gene delivery [1]. On the other hand, the
results of other studies showed that methylation is not
responsible for transient transgene expression in vivo after
adenovirus gene transfer in the mouse liver [7] and after
non-viral vectors delivery in the mouse lung [6]. In these
reports, promoter attenuation due to inflammatory processes
was proposed as an alternative mechanism for the decrease
in transgene expression.
To confirm that methylation of the CMV promoter is
associated with transcriptional silencing in muscle also after
non-viral gene delivery methods, as was demonstrated for
viral delivery [1], additional experiments were performed in
transiently transfected muscles carrying CMV promoter-
driven GFP. Treatment with 5-aza-2dC was performed
1 month after transfection, when the fluorescence intensity
of GFP reached ∼50% of the highest value [23], and we
could anticipate that there was enough time for methylation
to occur. After treatment, fluorescence intensity was signifi-
cantly increased compared to the control. Therefore, our
results indicate that methylation could be responsible for the
observed increase in fluorescence intensity after transient
transfection in muscle and support the results obtained in rat
muscle after adenoviral-mediated transfection [1].
The next part of our study dealt with the stress-induced
upregulation of the CMV promoter. We used the same
systems as for the methylation tests, but instead of treatment
with 5-aza-2dC, we utilized two standard anticancer treat-
Fig. 6. Fluorescence images of a TS/A EGFP tumors, and b transiently transfected muscles after different treatments.
Influence of treatment with 5-aza-2dC, IR, and CDDP on CMV activity in c TS/A-EGFP tumor model, and d transiently
transfected muscles. Results are expressed as the mean ± SE (*PG0.05).
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ments: local IR and systemic treatment with the chemo-
therapeutic agent CDDP that cause DNA damage. To avoid
the effect of methylation, freshly thawed cells were used in
the experiments. The exposure of cells to IR and CDDP
induced a significant increase in fluorescence intensity
compared to untreated controls. However, the magnitude of
this increase varied among the cell lines, being high in TS/A
EGFP cells and low in LPB EGFP cells. Furthermore, the
magnitude of induction was similar to that obtained with the
inducible p21 promoter. Therefore, in our study in LPB
cells, the CMV promoter was as inducible as the known
inducible p21 promoter [18, 19]. Similar observations have
been previously demonstrated for different cell lines using
different reporter genes and different delivery systems [13, 14,
39]. For example, the chemotherapeutic agent doxorubicin
was reported to upregulate CMV promoter-driven reporter
gene (luciferase) expression in stably transfected cell lines [14,
39] and after transient transfection using lipofectamine [14]
and an adenoviral vector [17]. IR (10 Gy) was also reported to
upregulate a CMV promoter-driven reporter gene in cells
transfected using electroporation [13].
In our study, significant upregulation of the CMV
promoter with IR and CDDP was also demonstrated in vivo
in tumors as well as in transiently transfected muscles.
Similar to our study, luminescence-based whole body
imaging showed upregulation of the CMV promoter
between 4 and 10 days after treatment of animals with
doxorubicin [14]. This upregulation of the CMV promoter is
of special importance when gene therapy is intended to be
combined with other standard cancer treatments, such as
radiotherapy and chemotherapy. Increased expression of the
therapeutic protein and consequently an increased therapeu-
tic effect can occur after treatment of patients with standard
therapy. Non-invasive imaging methods should be taken into
consideration when gene therapy is combined with treat-
ments that upregulate the promoter used in the gene therapy
vector, as non-invasive imaging can give the exact time
dependence of the activity of the promoter and therefore
optimal planning for the combination of therapies can be
achieved. Fluorescence imaging has in this case, an
advantage over luminescence imaging, since no additional
substrate is required for visualization of transgene expres-
sion and can be safely used over a prolonged period of time,
although with bioluminescence imaging lower levels of the
reporter gene can be detected [15].
Conclusions
Our study demonstrated that the CMV promoter can be
upregulated by different treatments. Observed alterations in
the activity of the CMV promoter limit the usefulness of this
widely used promoter as a constitutive promoter and high-
light the importance of proper choice of promoter linked to
the gene of interest for success of gene therapy as well as
basic research. On the other hand, inducibility of CMV
promoters can be beneficially used in gene therapy when
combined with standard cancer treatment, such as radio-
therapy and chemotherapy. Non-invasive imaging methods
have great potential for development of these treatment
combinations that will have an enhanced antitumor effect at
the same level of normal tissue damage.
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